Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients.
Doi T, Takiuchi H, Ohtsu A, Fuse N, Goto M, Yoshida M, Dote N, Kuze Y, Jinno F, Fujimoto M, Takubo T, Nakayama N, Tsutsumi R.
Doi T, et al. Among authors: ohtsu a.
Br J Cancer. 2012 Feb 14;106(4):666-72. doi: 10.1038/bjc.2011.590. Epub 2012 Jan 12.
Br J Cancer. 2012.
PMID: 22240796
Free PMC article.
Clinical Trial.